On June 9, 2020, Applied Molecular Transport (AMT), a clinical-stage biopharmaceutical company, announced the closing of its initial public offering of 12,650,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares, at a public offering price of $14.00 per share. The aggregate total gross proceeds to AMT from the offering were $177.1 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by AMT. AMT's common stock began trading on the Nasdaq Global Select Market on June 5, 2020, under the ticker symbol “AMTI."
The San Francisco-based company founded in 2010 is developing novel oral therapies for inflammatory diseases. Its pipeline contains lead candidate AMT-101, an oral GI-selective interleukin 10 that has completed a Phase 1b trial for ulcerative colitis. The company plans to initiate Phase 2 trials of AMT-101 in UC and related inflammatory indications between 2020 and 2021.
The Wilson Sonsini team that represented Applied Molecular Transport in the offering includes:
Corporate:
Ken Clark
Tony Jeffries
Michael Coke
Christina Poulsen
Lance Brady
Rachel Nagashima
Zack Lenox
Mary O'Brien
Marianne Stark Bradley
Patents:
Maya Skubatch
Rex Watkins
Jeff Seidel
Regulatory:
David Hoffmeister
Eva Yin
Privacy and Cybersecurity:
Matt Staples
Fintech:
Amy Caiazza
For more information, please see Applied Molecular Transport's press release.